共 108 条
[1]
Helmick CG(2008)Estimates of the prevalence of arthritis and other rheumatic conditions in the United States Arthritis Rheum 58 15-25
[2]
Felson DT(2008)American College of Rheumatology 2008 recommendations for the use of non-biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 762-84
[3]
Lawrence RC(2006)British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years) Rheumatology (Oxford) 45 1167-9
[4]
Saag KG(2005)Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Ann N Y Acad Sci 1051 799-810
[5]
Teng GG(2007)The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence Curr Opin Rheumatol 19 308-13
[6]
Patkar NM(2007)Interleukin-6: a key mediator of systemic and local symptoms in rheumatoid arthritis Bull NYU Hosp Jt Dis 65 S11-5
[7]
Luqmani R(2007)Relationship between serum concentrations of the interleukin-6 receptor inhibitor tocilizumab and C-reactive protein reduction in RA patients: 6 months’ data from a phase 3 study [abstract no. 259] Arthritis Rheum 56 148-9
[8]
Hennell S(2008)Drug-disease interaction study of tocilizumab in patients with rheumatoid arthritis: IL-6 signal inhbition normalized cytochrome P-450 enzymes expression which was reduced by inflammation [abstract no. FRI0166] Ann Rheum Dis 67 339-50
[9]
Estrach C(2008)Relationship between serum IL-6 levels after tocilizumab treatment and clinical remission in active rheumatoid arthritis patients [abstract no. OP-0135] Ann Rheum Dis 67 90-8
[10]
Voll RE(1988)Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes FEBS Lett 232 347-81